Human IL-23 p19 ELISA Kit
Protocol Booklet
Key features and details
- Specification:
- Sensitivity:
- Standard Curve Range:
- Standard Curve Gradient:
- Number of Incubations:
- Sample Volume:
- Assay type:
- Operation Duration:
-
Brand:
CAT.NO. : AEH0109
RMB Please choose
RMB Please choose
Size:
Trail, Bulk size or Custom requests Please contact us
*产品价格可能会有所调整，请以品牌方官网实时更新的价格为准，以确保准确性。
Product Details
Background
Interleukin 23 (IL-23) is a heterodimeric cytokine composed of two disulfide-linked subunits, a p19 subunit that is unique to IL-23, and a p40 subunit that is shared with IL-12. The p19 subunit has homology to the p35 subunit of IL-12, as well as to other single chain cytokines such as IL-6 and IL-11. The p40 subunit is homologous to the extracellular domains of the hematopoietic cytokine receptors. Mouse p19 cDNA encodes a 196 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and 177 aa mature protein. Human and mouse p19 share 70% aa sequence identity. Although p19 is expressed by activated macrophages, dendritic cells, T cells, and endothelial cells, only activated macrophages and dendritic cells express p40 concurrently to produce IL-23. The functional IL-23 receptor complex consists of two receptor subunits, the IL-12 receptor beta 1 subunit (IL-12 R beta 1) and the IL-23-specific receptor subunit (IL-23 R). IL-23 has biological activities that are similar to, but distinct from IL-12. Both IL-12 and IL-23 induce proliferation and IFN-gamma production by human T cells. While IL-12 acts on both na茂ve and memory human T cells, the effects of IL-23 is restricted to memory T cells. In mouse, IL-23 but not IL-12, has also been shown to induce memory T cells to secret IL-17, a potent proinflammatory cytokine. IL-12 and IL-23 can induce IL-12 production from mouse splenic DC of both the CD8- and CD8+ subtypes, however only IL-23 can act directly on CD8+ DC to mediate immunogenic presentation of poorly immunogenic tumor/self peptide
Typical Data
|
pg/ml |
O.D. |
Average |
Corrected |
|
|
0.00 |
0.0146 |
0.0163 |
0.0155 |
|
|
1.37 |
0.0224 |
0.0216 |
0.0220 |
0.0066 |
|
4.12 |
0.0360 |
0.0386 |
0.0373 |
0.0219 |
|
12.35 |
0.0823 |
0.0756 |
0.0790 |
0.0635 |
|
37.04 |
0.2068 |
0.2039 |
0.2054 |
0.1899 |
|
111.11 |
0.5727 |
0.5620 |
0.5674 |
0.5519 |
|
333.33 |
1.4960 |
1.4830 |
1.4895 |
1.4741 |
|
1000.00 |
3.4620 |
3.3150 |
3.3885 |
3.3731 |
Precision
|
Intra-assay Precision |
|
Inter-assay Precision |
|||||
|
Sample Number |
S1 |
S2 |
S3 |
S1 |
S2 |
S3 |
|
|
22 |
22 |
22 |
6 |
6 |
6 |
||
|
Average（pg/ml） |
21.7 |
101.7 |
296.8 |
20.6 |
102.9 |
318.1 |
|
|
Standard deviation |
1.0 |
3.1 |
26.8 |
1.0 |
3.1 |
11.3 |
|
|
Coefficient of variation（%） |
4.4 |
3.0 |
4.2 |
5.1 |
3.0 |
3.5 |
|
- Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
- Inter-assay Precision (Precision between assays)Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human IL-23 p19 into health human serum sample. The un-spiked serum was used as blank in this experiment. The recovery ranged from 81% to 112% with an overall mean recovery of 96%.
Sample Values
|
Sample Matrix |
Sample Evaluated |
Range (pg/ml) |
Detectable % |
Mean of Detectable (pg/ml) |
|
Serum |
30 |
n.d.-6.26 |
25 |
0.69 |
Serum/Plasma - Thirty samples from apparently healthy volunteers were evaluated for the presence of human IL-23 p19 in this assay. No medical histories were available for the donors.
New Products
